Brief: Acer Therapeutics And Relief Therapeutics Announce U.S. FDA Approval Of Olpruva

MindMaze Therapeutics Holding SA

27/12/2022 14:04

Dec 27 (Reuters) - Acer Therapeutics Inc  ACER.O :
    * ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE U.S.
FDA
APPROVAL OF OLPRUVA™ FOR PATIENTS WITH UREA CYCLE DISORDERS
    * ACER THERAPEUTICS INC - $42.5 MILLION OF NON-DILUTIVE DEBT
FUNDING AVAILABLE TO ACER THAT, IF DRAWN, WOULD EXTEND CASH
RUNWAY INTO H2 2023
    * ACER THERAPEUTICS INC - NEW FDA-APPROVED FORMULATION FOR
PATIENTS LIVING WITH UREA CYCLE DISORDERS
    * ACER THERAPEUTICS INC - NOT CURRENTLY PROVIDING SPECIFIC
REVENUE
OR OPERATING EXPENSE GUIDANCE FOR OLPRUVA

Source text for Eikon:  ID:nGNX9LJDwt 
Further company coverage:  ACER.O 
 ((reuters.briefs@thomsonreuters.com;))